{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:54:56Z","timestamp":1791381296399,"version":"4.3.3"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.metabol.2014.08.007","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T17:34:11Z","timestamp":1408556051000},"page":"1439-1446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients"],"prefix":"10.1016","volume":"63","author":[{"given":"Luigi","family":"Marzano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GianLuca","family":"Colussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Del Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo A.","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Catena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2014.08.007_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-115-3-209","article-title":"Lipoprotein(a) and atherosclerosis","volume":"115","author":"Scanu","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.metabol.2014.08.007_bb0010","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/clinchem\/40.4.574","article-title":"Biological variability of cholesterol, triglyceride, low- and high-density lipoprotein cholesterol, lipoprotein(a), and apolipoproteins A-I and B","volume":"40","author":"Marcovina","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2014.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1046\/j.1523-1755.1999.00621.x","article-title":"Lipoprotein(a), apolipoprotein(a) isoforms, and proteinuria in patients with moderate renal failure","volume":"56","author":"Sechi","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2014.08.007_bb0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0025","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S1567-5688(09)71817-3","article-title":"Cardiovascular events in patients with increased lipoprotein(a)\u2014retrospective data analysis in an outpatient department of lipid disorders","volume":"10","author":"Tselmin","year":"2009","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.metabol.2014.08.007_bb0035","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/jama.1997.03540450045033","article-title":"Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension","volume":"277","author":"Sechi","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2014.08.007_bb0040","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1097\/01.hjh.0000178835.33976.e7","article-title":"New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a)","volume":"23","author":"Catena","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2014.08.007_bb0045","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/0026-0495(92)90019-7","article-title":"Insulin hypersecretion: a distinctive feature between essential and secondary hypertension","volume":"41","author":"Sechi","year":"1992","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.08.007_bb0050","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1524-6175.2003.01764.x","article-title":"Insulin resistance, hypertension, and coronary heart disease","volume":"5","author":"Reaven","year":"2003","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.metabol.2014.08.007_bb0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2840-11-81","article-title":"High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain","volume":"11","author":"Boronat","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0060","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.ATV.18.8.1335","article-title":"Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype","volume":"18","author":"Rainwater","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0065","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2337\/diab.41.10.1341","article-title":"Inverse relationship between serum Lp(a) levels and first-phase insulin secretion","volume":"41","author":"Sidhu","year":"1992","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2014.08.007_bb0070","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0002-9343(00)00567-2","article-title":"Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance","volume":"109","author":"Catena","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2014.08.007_bb0075","first-page":"865","article-title":"Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events","volume":"84","author":"Sechi","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.metabol.2014.08.007_bb0080","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1515\/CCLM.2004.114","article-title":"First WHO\/IFCC International reference reagent for lipoprotein(a) for immunoassay-Lp(a) SRM 2B","volume":"42","author":"Dati","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.metabol.2014.08.007_bb0085","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2337\/diabetes.51.4.1226","article-title":"Abnormalities of glucose metabolism in patients with early renal failure","volume":"51","author":"Sechi","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2014.08.007_bb0090","author":"National Heart LaBIaBUFHS","year":"2013","journal-title":"General Cardiovascular Disease (10-year risk). Last update February 7, 2013"},{"key":"10.1016\/j.metabol.2014.08.007_bb0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2014.08.007_bb0100","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.08.007_bb0105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1172\/JCI115855","article-title":"Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations","volume":"90","author":"Boerwinkle","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2014.08.007_bb0110","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/MOL.0b013e3283598d81","article-title":"Emerging therapeutic agents to lower lipoprotein(a) levels","volume":"23","author":"Kolski","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0021-9150(93)90102-Z","article-title":"The effects of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover","volume":"101","author":"Seed","year":"1993","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2014.08.007_bb0120","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2174\/157016111797484071","article-title":"Lipoprotein(a): current perspectives","volume":"9","author":"Gouni-Berthold","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00004872-200302000-00018","article-title":"Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage","volume":"21","author":"Catena","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2014.08.007_bb0130","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.clnu.2004.08.001","article-title":"Omega-3 polyunsaturated fatty acids decrease plasma lipoprotein(a) levels in hypertensive subjects","volume":"3","author":"Colussi","year":"2004","journal-title":"Clin Nutr"},{"key":"10.1016\/j.metabol.2014.08.007_bb0135","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/00004872-200018060-00008","article-title":"Lipoprotein(a), hemostatic variables, and cardiovascular damage in hypertensive patients","volume":"18","author":"Sechi","year":"2000","journal-title":"J Hypertens"},{"key":"10.1016\/j.metabol.2014.08.007_bb0140","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2337\/diacare.14.4.302","article-title":"Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects","volume":"14","author":"Haffner","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2014.08.007_bb0145","first-page":"28","article-title":"Lipoprotein(a) is associated with basal insulin levels in patients with type 2 diabetes mellitus","volume":"93","author":"Habib","year":"2009","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.metabol.2014.08.007_bb0150","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2337\/diacare.17.10.1135","article-title":"The relationship between serum lipoprotein(a) and insulinemia in healthy nondiabetic adult men","volume":"17","author":"Duell","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2014.08.007_bb0155","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1053\/meta.2001.20195","article-title":"Differential effects of obesity with and without hyperinsulinemia on plasma lipoprotein(a) concentrations in men","volume":"50","author":"Posadas-Romero","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.08.007_bb0160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3181\/00379727-208-43862C","article-title":"Genetic factors determine the blood pressure response to insulin resistance and hyperinsulinemia: a call to refocus the insulin hypothesis of hypertension","volume":"208","author":"Mark","year":"1995","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.metabol.2014.08.007_bb0165","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1046\/j.1523-1755.2003.00313.x","article-title":"Insulin receptors and renal sodium handling in fructose-fed rats","volume":"64","author":"Catena","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2014.08.007_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s001250051110","article-title":"Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes","volume":"42","author":"Neele","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2014.08.007_bb0175","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/sj.ki.5002240","article-title":"Evidence mounts for a role of the kidney in lipoprotein(a) catabolism","volume":"71","author":"Albers","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2014.08.007_bb0180","first-page":"143","article-title":"Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin","volume":"17","author":"Derosa","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"10.1016\/j.metabol.2014.08.007_bb0185","first-page":"174","article-title":"Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy","volume":"27","author":"Habib","year":"2006","journal-title":"Saudi Med J"},{"key":"10.1016\/j.metabol.2014.08.007_bb0190","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/147323000503300303","article-title":"Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin- treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial","volume":"33","author":"Derosa","year":"2005","journal-title":"J Int Med Res"},{"key":"10.1016\/j.metabol.2014.08.007_bb0195","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jdiacomp.2005.05.009","article-title":"Diabetes treatments have differential effects on nontraditional cardiovascular risk factors","volume":"20","author":"Fonseca","year":"2006","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.metabol.2014.08.007_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0026-0495(99)90001-X","article-title":"Relationships between apolipoprotein(a) phenotype and increase of lipoprotein(a) by troglitazone","volume":"48","author":"Matsumoto","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.08.007_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.diabres.2006.12.022","article-title":"Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders","volume":"77","author":"Igarashi","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2014.08.007_bb0210","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2006.05.012","volume":"28","author":"Derosa","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2014.08.007_bb0215","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2710.2006.00756.x","article-title":"Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome","volume":"31","author":"Derosa","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.metabol.2014.08.007_bb0220","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2169\/internalmedicine.46.0320","article-title":"Effects of natiglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized trial","volume":"46","author":"Derosa","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.metabol.2014.08.007_bb0225","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.metabol.2005.04.010","article-title":"The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study","volume":"54","author":"Sarafidis","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2014.08.007_bb0230","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2265.2007.02985.x","article-title":"The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome","volume":"67","author":"Sahin","year":"2007","journal-title":"Clin Endocrinol"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514002443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049514002443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:04:22Z","timestamp":1758427462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049514002443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0026049514002443"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2014.08.007","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2014.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}